Viatris Inc
VTRS · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2017–FY2025
- History
- 9 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Viatris Inc at a glance
In FY2025, Viatris Inc reported revenue of USD 28,550 mn, EBITDA of USD 17,254 mn, EBITDA margin of 60.4%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 29,432 | 28,550 | |||
| EBITDA | 18,268 | 17,254 | |||
| EBITDA margin | 62.1% | 60.4% | |||
| Free cash flow | 1,977 | 1,937 | |||
| ROIC | 111.0% | 112.4% |
The full 9-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas